Biotech/Healthcare
The company has successfully designed a gene therapy candidate for Leber hereditary optic neuropathy (LHON). To date, it has completed clinical trials involving 152 LHON patients, including seven patients in Argentina.
Source: ChinaBulls — chinabulls.com
Last updated 2023-08-01
Create Account to Unlock Full Data for Free
Get access to market data, insights, backers, analytics and funding rounds.